Search

The article reports that numerous subscale scores of the Aberrant Behavior Checklist-Community (ABC-C) for autistic children taking adjunctive pentoxifylline with risperidone have been greatly reduced as compared to those receiving placebo with risperidone. Children in the pentoxifylline and placebo groups have mean ages of 8 years and 7.4 years respectively. The hypothesis of an immune system disorder of autism may have been supported by the efficacy of pentoxifylline in the study.

Autism has no pharmaceutical treatment; however, risperidone is used in managing irritability associated with the disorder. Building on evidence that autism may be related to inflammation, researchers looked at the minocycline, a tetracycline antibiotic, in combination with risperidone in treating children with autism. [ABSTRACT FROM AUTHOR]

The article presents the study regarding the efficacy of risperidone and quetiapine to treat adolescent patients with first-onset psychosis. It mentions that 22 patients were given random open-label treatment with ≤800 milligrams of quetiapine per day (mg/day) or risperidone ≤6 mg/day for six weeks. It states only two patients remained in the hospital due to severity of their illness and quetiapine was found more effective compared to risperidone.

The article presents three case studies regarding the treatment of girls with obsessive compulsive disorder (OCD), using sertraline and risperidone. In case 1, a four-year-old girl was presented with anxiety, intrusive thoughts and lack of appetite. In the 2nd case, a four and a half year old girl was presented for excessive cleaning and washing. A five year old girl was reported for intrusive thoughts of religious nature. Clinical trials were conducted to assess the treatment of the 3 girls.

The article offers information on the result of the study related to the use extended risperidone treatment to the children aged 7-17 in the U.S. It emphasizes that the extended risperidone treatment resulted in the potential increase of the participant's weight and body mass index (BMI). The article further mentions the use of concomitant psychotropic medication while the study is in progress.

The article reports on the result of the study on the effects of antipsychotic to young patients. It shows a higher risk of neurological adverse events with risperidone, multiple antipsychotics or serotonin-specific reuptake inhibitors. It reveals increased odds of involuntary movements, seizures and sedation in youths treated with psychotic medications compared with untreated controls.

The article reports on the study conducted to 38 children randomized to risperidone or placebo under double-blind conditions for eight weeks. Results show that risperidone does not appear to impair cognitive function in children with autism. According to the authors of the study, risperidone did not appear to contribute to impairment in any of the cognitive domains. Further research is needed to determine the robustness and extent of any favourable effects on cognitive performance.

The article offers news briefs related to pharmacology. An open-label study found that Riluzole could benefit pediatric patients with treatment-resistant obsessive-compulsive disorder (OCD). Risperidone and haloperidol may play a beneficial role in improving affect and social skills in autistic children. Ziprasdidone shows benefits in improving manic symptoms in children and adolescents with bipolar disorder.

The article offers information on the risperidone risperdal, an atypical antipsychotic drug. Risperidone has U.S. Food and Drug Administration-approved indications for the treatment of schizophrenia in adults and for the short-term treatment of acute mania or mixed episodes associated with bipolar disorder in adults. Adverse effects associated with it include dizziness, weight gain and constipation. Interactions with other medications are also tackled.

The article reports on a study on the effects of risperidone on cognitive function in children with disruptive behaviors in the U.S. It revealed that risperidone does not alter cognitive function in children with subaverage IQ and disruptive behavior disorders and that cognitive function was maintained or improved during one year of risperidone treatment. These findings offered information for both clinicians and parents in the evaluation of benefits and risks of risperidone treatment.

The article reports on a study of risperidone (Risperidal) treatment for aggression in male children with disruptive behavioral disorders (DBDs) and below average intelligence. John C. LeBlanc and colleagues found that risperidone is an effective treatment for behavioral symptoms in children with DBDs and low intelligence quotient. They said that long-term safety should be compared with other antipsychotics such as mood stabilizers. INSET: Testing response by subtype: predatory versus impulsive.

The article presents information on the antipsychotic drug risperidone. It is reported that risperidone has FDA-approved indications for the treatment of schizophrenia and for the short-term treatment of acute mania or mixed episodes associated with bipolar disorder in adults, both as a monotherapy and in combination with lithium or valproate. Adverse effects associated with risperidone include: dizziness, sensation that one has to walk or pace (akathisia), weight gain, headache, constipation, upset stomach, nausea, drowsiness, tiredness, sun-sensitivity, and sexual dysfunction.

The article provides information on atypical antipsychotic drug with generic name risperidone and brand name risperdal. It is used for the treatment of schizophrenia and for the short-term treatment of acute mania or mixed episodes associated with bipolar disorder in adults. The common side effects include dizziness, weight gain, headache, constipation and nausea. Drugs that interact with risperidone include carbamazepine, clozapine and fluoxetine. The drug can be stored at a controlled room temperature in a tightly-closed, light- and moisture-resistant container. The dose should start low, and increased slowly based on clinical response and adverse effects.

The article reports that a relatively large-scale placebo controlled study published in the November 2004 issue of "Pediatrics," investigated the efficacy and safety of the atypical antipsychotic risperidone for the treatment of disruptive behaviors in children with autism and other pervasive developmental disorders (PDD). Results were encouraging on all other subscales of the ABC, with the most significant difference observed for the hyperactivity/noncompliance subscale, for which risperidone-treated subjects experienced a decrease of 14.9 in mean score, while placebotreated subjects experienced a decrease of 7.4.

When tic suppression, electrocardiogram changes, weight gain, and side effect profiles of once-daily pimozide were compared with twice-daily risperidone in children and adolescents with tic disorders, researchers found that risperidone appeared superior to pimozide for tic suppression, but was associated with greater weight gain. Participants in this randomized, double-blind, crossover study were 19 children aged 7 to 17 who had Tourette' s or chronic motor tic disorder. Diagnoses of Tourette's disorder and chronic motor tic disorders were made using DSM-IV-TR criteria.

Provides information regarding the antipsychotic risperidone. Common usage; Major side effects; Diseases associated with atypical antipsychotic medications; Interactions with other medications; Common dosages; Identification; Storage.

Reports on the positive clinical effects seen in adolescent patients with prodromal symptoms and a family history of schizophrenia, when they were subjected to an open label trial of low dose risperidone. Assessment of symptoms in both prodromal and first-episode patients after initial risperidone dosage; Effect of low dose and short-term treatment of risperidone on behavioral and neurocognitive functioning.

Reports on the series of clinical investigations to evaluate medications used to treat autism, attention-deficit/hyperactivity disorder anxiety and other disorders in children and adolescents in the U.S. Aim of Research Units on Pediatric Psychopharmacology; Standardization in the assessment of adverse events in studies of medications; Extended use of risperidone in autism.

Presents news related to studies conducted in the field of medical science as of February 2002. Efficacy of the drug, risperidone, in treating symptoms of Tourette Syndrome; Effect of tricyclic antidepressants on myocardial function.

Reports on studies conducted by researchers from Montreal, Canada on the use of risperidone in children with disruptive behavior disorders, low intelligence quotient and attention deficit-hyperactivity disorder (ADHD). Profile of the study subjects; Comparison of the effects of the drug on hyperactivity and other symptoms in patients with ADHD; Effects of long term use of risperidone.

Reports on research works on child and adolescent psychopharmacology. Target dose of risperidone; Effectiveness of citalopram for adolescent depression; Additional health benefits of ziprasidone; Study of the use of amantadine for autistic symptoms.

Reports on developments related to psychopharmacology as of March 2001. Study comparing risperidone and pimozide for the treatment of Tourette's disorder; Mechanism of action of methylphenidate for the treatment of attention-deficit/hyperactivity disorder; Safety reporting in drug trials.

Reports on child and adolescent psychopharmacology research results. Similar fluoxetine accumulation profiles in youths and adults; Treatment of behavioral disorders with risperidone oral solution.

Presents information about the antipsychotic drug risperidone or Risperdal. Side effects; Interactions with other medications; Common dosages.

Studies the effectiveness and tolerability of risperidone in treating juvenile mania in patients with bipolar disorder. Average dose the children received; Highlights of the study by Jean A. Frazier, Michele C. Meyer, and Joseph Biederman et al at Massachusetts General Hospital in Boston, Massachusetts.

Highlights the results of a study to determine whether risperidone was superior to placebo in children and adolescents with conduct disorder. Suggestion that children should receive the drug at low doses and that doses should be carefully titrated to prevent side effects; Efficacy of the drug.

The article reports that the U.S. Food and Drug Administration (FDA) has announced on November 4, 2013 the decision of Janssen Pharmaceuticals Inc. to declare a guilty plea for its marketing of its schizophrenia drug, Risperdal, without approval.

The article offers information on a study which examines the efficacy of serotonin-specific reuptake inhibitors' (SSRIs) with aripiprazole or risperidone in young patients with tic-related obsessive-compulsive disorder (OCD).

The article reports on a study which examines the link of body iron status to psychiatric symptom severity, treatment response, and tolerability after extended treatment with risperidone in pediatric patients.

The article offers information on an ongoing research which deals with the association of akathisia with suicidal ideation.

The article presents a retrospective study on the systematic review of evidence on the medication treatment for 13 to 30-years-old with autism spectrum disorders (ASDs). The study involves searched Medline, ERIC, and Psyc-INFO databases from 1980 to December 2011. The results highlight the lack of evidence on all care areas for young adults and adolescents with ASD.

The article reports on the findings of a study on the efficacy of risperidone in improving maladaptive behaviors in autism.

The article discusses the site characteristics in comparing the efficacy between risperidone and lithium in patients wiithout attention-deficit hyperactivity disorder (ADHD).

The article reports on the findings of a study which investigates the efficacy of a cyclooxygenase-2 inhibitor added to risperidone in the treatment of autism.

The article offers updates from the U.S. Food and Drug Administration (FDA) on psychopharmacology-related drug approvals including the first generic version of Lexapro, lisdexamfetamine capsules of Shire Pharmaceuticals Group PLC, and labeling revisions for donepezil, ramelteon and ketamine.

The article reports that adolescents and children being treated with risperidone for autism spectrum disorder, experience weight gain after 1 month.

The article presents a case study of a 15-year-old boy who was diagnosed with autistic disorder, mental retardation, and Tourette Syndrome and had undergone oculogyric crises caused by low-dosed risperidone.

The article presents a study which states that risperidone helps in reducing irritability in pediatric patients with severe mood dysregulation (SMD).

In this article the authors offer information on a clinical study carried out on children in the U.S. to examine effects of risperidone on weight gain in relation to genetic factors in youth with autism spectrum disorder. After 8 weeks of treatment, the variant T allele of the 759C/T HTR2C promoter polymorphism was protective against risperidone-induced weight gain. Authors suggest genotyping may someday become standard practice when treating youth with antipsychotic agents.

The article reports on a study which found that liquid risperidone could be safe and efficient in reducing rage duration in children with severe mood dysregulation (SMD) or possible bipolar disorder in the U.S.

In this article, the author comments on the research done on the effects of risperidone in treating acute manic symptoms in youths with bipolar I disorders. The author mentions that before researchers interpret the results of the study, one must evaluate the impact of the medication on the target population. Moreover, despite the limitations of the research, he suggests to find the lower-dose range which had better benefit-risk ratio than higher dose range.

The article reports on a study which found that high risperidone dosing in adolescents with acute episode of schizophrenia showed greater improvement in positive and negative symptoms. The double blind, randomized study compared high and low dosing regimen of risperidone. Results of the study suggested that resperidone at 1.5-6.0 milligram/day offers a favorable benefit-to-risk profile for schizophrenia treatment in adolescents.

The article reports on two drugs that has been approved by the U.S. Food & Drug Administration (FDA). Seroquel XR, also called as once-daily quetiapine, is implied as the first medication approved by the FDA for once-daily acute treatment of both depressive and manic episodes linked with bipolar disorder. Likewise, a new injection site has been approved by the FDA, the deltoid muscle, for risperidone long-acting injection or risperdal consta, previously approved only as a gluteal injection.

The article reports that the U.S. Food and Drug Administration (FDA) has approved the various drugs, which include generic divalproex sodium, generic risperidone, and methylphenidate. Generic divalproex sodium is approved for treatment of seizures, bipolar disorder, and migraine headaches. Risperidone is used for treating schizophrenia, bipolar disorder, and other psychiatric conditions. Methylphenidate is approved for treating attention-deficit/hyperactivity disorder (ADHD).

The article presents a case study of an 11-year-old boy with attention-deficit/hyperactivity disorder (ADHD) who was referred because of hyperactivity, anger, aggression and inattention. Atomoxetine was started to the patient, resulting in improved concentration and attention but with no effect on hyperactivity. He also received risperidone but the patient experienced painless, frequent penile erections. He continued to have penile erections, but fully recovered when the drug was stopped.

The article presents a case study of an 18-year old boy who had been diagnosed with attention deficit hyperactivity disorder (ADHD). He was treated with dexamphetamine spansules and at age 16, he began to experience decreased functioning. Two days after the discontinuance of dexamphetamine treatment, he experienced an acute dystonic reaction with torticollis and was given risperidone. He was able to recover with no recurrence of dystonia while his behavior improved.

The article offers news briefs related to medical research. The U.S. Food and Drug Administration (FDA) has sent an approval letter to Johnson & Johnson Pharmaceuticals Research & Development regarding the two supplemental New Drug Applications (sNDAs) for Risperdal. The National Institutes of Health (NIH) conducted a study on brain development and finds out that children age 11 or 12 appears to be near adult levels of performance on many cognitive and motor skills.

The article presents three case reports of children with attention-deficit hyperactivity disorder (ADHD) who developed severe adverse reactions of risperidone to methylphenidate switch. A five year old male suffered from severe behavioral reactions after the drug switching. Another is a six-year-old female who discontinued her risperidone medication. Another 15-year-old female suffered from agitation, irritability and discomfort after the drug switching.